VM-902A
VM-902A is an investigational drug currently under development for the treatment of neurodegenerative diseases, particularly Alzheimer's disease. It is a small molecule that has shown promise in preclinical studies for its potential neuroprotective and cognitive-enhancing effects.
Mechanism of Action[edit | edit source]
VM-902A is believed to exert its effects through multiple mechanisms. It is thought to modulate neurotransmitter systems, including the cholinergic system, which is crucial for memory and learning. Additionally, VM-902A may have antioxidant properties that help reduce oxidative stress, a contributing factor in neurodegeneration.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of VM-902A is still under investigation. Preliminary studies suggest that it is orally bioavailable and has a moderate half-life, allowing for convenient dosing schedules. Further studies are needed to fully elucidate its absorption, distribution, metabolism, and excretion (ADME) characteristics.
Clinical Trials[edit | edit source]
As of the latest updates, VM-902A is undergoing Phase II clinical trials. These trials aim to assess its efficacy and safety in patients with mild to moderate Alzheimer's disease. Initial results have been promising, showing improvements in cognitive function and daily living activities compared to placebo.
Potential Side Effects[edit | edit source]
The safety profile of VM-902A is still being established. Common side effects observed in early trials include mild gastrointestinal disturbances and headache. No serious adverse events have been reported thus far, but ongoing studies will provide more comprehensive safety data.
Research and Development[edit | edit source]
VM-902A is being developed by a consortium of academic and industry partners. The development process involves extensive collaboration to optimize its therapeutic potential and ensure regulatory compliance. The drug's development is supported by funding from various governmental and non-governmental organizations dedicated to advancing treatments for neurodegenerative diseases.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
